Literature DB >> 12431971

Function and health status outcomes in a randomized trial comparing preoperative and postoperative radiotherapy in extremity soft tissue sarcoma.

A M Davis1, B O'Sullivan, R S Bell, R Turcotte, C N Catton, J S Wunder, P Chabot, A Hammond, V Benk, M Isler, C Freeman, K Goddard, A Bezjak, R A Kandel, A Sadura, A Day, K James, D Tu, J Pater, B Zee.   

Abstract

PURPOSE: Morbidity associated with wound complications may translate into disability and quality-of-life disadvantages for patients treated with radiotherapy (RT) for soft tissue sarcoma (STS) of the extremities. Functional outcome and health status of extremity STS patients randomized in a phase III trial comparing preoperative versus postoperative RT is described. PATIENTS AND METHODS: One hundred ninety patients with extremity STS were randomized after stratification by tumor size dichotomized at 10 cm. Function and quality of life were measured by the Musculoskeletal Tumor Society Rating Scale (MSTS), the Toronto Extremity Salvage Score (TESS), and the Short Form-36 (SF-36) at randomization, 6 weeks, and 3, 6, 12, and 24 months after surgery.
RESULTS: One hundred eighty-five patients had function data. Patients treated with postoperative RT had better function with higher MSTS (25.8 v 21.3, P <.01), TESS (69.8 v 60.6, P =.01), and SF-36 bodily pain (67.7 v 58.5, P =.03) scores at 6 weeks after surgery. There were no differences at later time points. Scores on the physical function, role-physical, and general health subscales of the SF-36 were significantly lower than Canadian normative data at all time points. After treatment arm was controlled for, MSTS change scores were predicted by a lower-extremity tumor, a large resection specimen, and motor nerve sacrifice; TESS change scores were predicted by lower-extremity tumor and prior incomplete excision. When wound complication was included in the model, patients with complications had lower MSTS and TESS scores in the first 2 years after treatment.
CONCLUSION: The timing of RT has minimal impact on the function of STS patients in the first year after surgery. Tumor characteristics and wound complications have a detrimental effect on patient function.

Entities:  

Mesh:

Year:  2002        PMID: 12431971     DOI: 10.1200/JCO.2002.03.084

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN: 0732-183X            Impact factor:   44.544


  56 in total

1.  Variation in the gross tumor volume and clinical target volume for preoperative radiotherapy of primary large high-grade soft tissue sarcoma of the extremity among RTOG sarcoma radiation oncologists.

Authors:  Dian Wang; Walter Bosch; David G Kirsch; Rawan Al Lozi; Issam El Naqa; David Roberge; Steven E Finkelstein; Ivy Petersen; Michael Haddock; Yen-Lin E Chen; Naoyuki G Saito; Ying J Hitchcock; Aaron H Wolfson; Thomas F DeLaney
Journal:  Int J Radiat Oncol Biol Phys       Date:  2011-01-27       Impact factor: 7.038

Review 2.  Recent advances in radiotherapy for soft-tissue sarcoma.

Authors:  Brian O'Sullivan; Iain Ward; Charles Catton
Journal:  Curr Oncol Rep       Date:  2003-07       Impact factor: 5.075

3.  Protecting a patellar ligament reconstruction after proximal tibial resection: a simplified approach.

Authors:  Vijay Titus; Mark Clayer
Journal:  Clin Orthop Relat Res       Date:  2008-04-19       Impact factor: 4.176

4.  Soft tissue sarcoma clinical practice guidelines in oncology.

Authors:  George D Demetri; Laurence H Baker; Derrick Beech; Robert Benjamin; Ephraim S Casper; Ernest U Conrad; Thomas F DeLaney; David S Ettinger; Martin J Heslin; Ray J Hutchinson; Krystyna Kiel; William G Kraybill; G Douglas Letson; James Neff; Richard J O'Donnell; I Benjamin Paz; Raphael E Pollock; R Lor Randall; Karen D Schupak; Douglas S Tyler; Margaret von Mehren; Jeffrey Wayne
Journal:  J Natl Compr Canc Netw       Date:  2005-03       Impact factor: 11.908

5.  RTOG sarcoma radiation oncologists reach consensus on gross tumor volume and clinical target volume on computed tomographic images for preoperative radiotherapy of primary soft tissue sarcoma of extremity in Radiation Therapy Oncology Group studies.

Authors:  Dian Wang; Walter Bosch; David Roberge; Steven E Finkelstein; Ivy Petersen; Michael Haddock; Yen-Lin E Chen; Naoyuki G Saito; David G Kirsch; Ying J Hitchcock; Aaron H Wolfson; Thomas F DeLaney
Journal:  Int J Radiat Oncol Biol Phys       Date:  2011-06-15       Impact factor: 7.038

6.  Pathologic complete response of a malignant peripheral nerve sheath tumor in the lung treated with neoadjuvant Ifosfamide and radiation therapy.

Authors:  Kyle C Cuneo; Richard F Riedel; Leslie G Dodd; David H Harpole; David G Kirsch
Journal:  J Clin Oncol       Date:  2012-08-06       Impact factor: 44.544

7.  Nonrhabdomyosarcoma soft tissue sarcoma (NRSTS) in pediatric and young adult patients: Results from a prospective study using limited-margin radiotherapy.

Authors:  Christopher L Tinkle; Israel Fernandez-Pineda; April Sykes; Zhaohua Lu; Chia-Ho Hua; Michael D Neel; Armita Bahrami; Barry L Shulkin; Sue C Kaste; Alberto Pappo; Sheri L Spunt; Matthew J Krasin
Journal:  Cancer       Date:  2017-07-31       Impact factor: 6.860

Review 8.  Resection and reconstruction of pelvic and extremity soft tissue sarcomas with major vascular involvement: Current concepts.

Authors:  Niall P McGoldrick; Joseph S Butler; Maire Lavelle; Stephen Sheehan; Sean Dudeney; Gary C O'Toole
Journal:  World J Orthop       Date:  2016-05-18

9.  Guidelines for the management of soft tissue sarcomas.

Authors:  Robert Grimer; Ian Judson; David Peake; Beatrice Seddon
Journal:  Sarcoma       Date:  2010-05-31

10.  Agreement among RTOG sarcoma radiation oncologists in contouring suspicious peritumoral edema for preoperative radiation therapy of soft tissue sarcoma of the extremity.

Authors:  Houda Bahig; David Roberge; Walter Bosch; William Levin; Ivy Petersen; Michael Haddock; Carolyn Freeman; Thomas F Delaney; Ross A Abrams; Danny J Indelicato; Elizabeth H Baldini; Ying Hitchcock; David G Kirsch; Kevin R Kozak; Aaron Wolfson; Dian Wang
Journal:  Int J Radiat Oncol Biol Phys       Date:  2013-03-06       Impact factor: 7.038

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.